Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vets warned of monensin toxicity in dogs
dog walking
So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.
SPC for Kexxtone changed after rise in accidental exposure reports
 
Veterinary surgeons are being warned of the risks of monensin exposure to non-target species.

In 2015, the Veterinary Medicines Directorate (VMD) saw an increase in reports of accidental canine exposure to Kexxtone 32.4g (monensin), the drug used in cattle feed to control ketosis.

Reported symptoms included neurological issues, such as seizures, lethargy, muscular problems, locked jaws, problems with balance, confusion, vomiting and death.

So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.

As a result, the VMD requested that the following warning be added to the Summary of Product Characteristics (SPC):

'Do not allow dogs, horses, other equines or guinea fowl access to formulations containing monensin. Due to the risk of bolus regurgitation, do not allow these species access to areas where treated cattle have been kept. Ingestion or oral exposure to monensin can be fatal in these species.'

Writing in Veterinary Record letters, the VMD suggested that when prescribing Kexxtone, vets should advise clients of the dangers to non-target species, whilst also remaining aware of the effects of monensin when dealing with cases that present neurological or myopathic problems.

Vets are encouraged to report all adverse reactions to the applicable marketing authorisation holder, or to the VMD via: www.gov.uk/report-veterinary-medicine-problem

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'